Europe Monoclonal Antibody Therapy Market

Europe Monoclonal Antibody Therapy Market Size (2023 to 2028)

The market size for monoclonal antibody therapy in the European region was worth USD 57.52 billion in 2023. This value is further estimated to be growing at a CAGR of 15.35% from 2023 to 2028 and worth USD 117.47 billion by 2028.

In the medical field, monoclonal products are in high demand. It has the potential to be a matching treatment for a variety of ailments. In addition, this cell is commonly employed in cancer treatment. These procedures make using a monoclonal antibody to target cancer cells. All of these reasons will boost the market value of Europe's monoclonal antibody therapy market during the forecast period. Furthermore, market demand was fueled by technological advancements. The healthcare industry has seen significant technical improvements in recent years. As a result, better treatments for chronic disorders are possible. Furthermore, patients can now receive cost-effective and effective cancer treatment due to next-generation sequencing.

During the forecast period, technological advancements boost the total revenue of the monoclonal antibody therapy market in Europe. In addition, as the public becomes more aware of antibody therapy, demand increases. Monoclonal antibodies are lab-made proteins that stimulate the immune system's ability to defend against dangerous antigens like viruses. Antibodies that specifically target antigens are known as monoclonal antibodies.

Furthermore, the monoclonal antibody therapeutics market will benefit from increased use in private clinics, hospitals, and research institutes. Strategic partnerships help companies expand their operations while strengthening their positions in the monoclonal antibody therapies market. Such innovations contribute to the monoclonal antibody therapies market's overall growth. Factors such as expanding awareness about the use of monoclonal antibody therapies to treat a variety and, as well as substantial investments by various organizations and conglomerates as a result of the market's growing popularity will boost the market's growth. Furthermore, increased healthcare infrastructure would contribute to the monoclonal antibody therapies market's growth in the European region.

However, government regulations limit the total growth of the monoclonal antibody therapy market. Monoclonal antibody medicines necessitate a high level of compliance. Compliance standards are holding up antibody medication uptake. The revenue rates may be harmed by a lack of demand in this developing region. As a result of these issues, the market's growth pace may slow.

This research report on the European monoclonal antibody therapy market has been segmented and sub-segmented into the following categories.

By Type:

• Human mAb
• Humanized mAb
• Chimeric mAb
• Murine mAb

By Application:

• Cancer
• Autoimmune Diseases

By Distribution Channel:

• Hospital Pharmacy Retail Pharmacy
• Online Pharmacy

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The use of monoclonal antibodies (mAbs) has increased in European hospitals. Hospitals are anticipated to see a rise in therapeutic proteins as the demand for autoimmune diseases, and cancer treatment grows. Following reimbursement regulations and government activities supporting the use of mAbs, patients have exhibited a greater preference for hospitals. As a result, monoclonal antibody therapies have acquired a lot of attention to prevent infections and reduce hospital admissions. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom got the green light for the first monoclonal antibody medication to prevent and treat COVID-19 in August 2022. The regional expansion is expected to be fueled by the increasing availability of mAb medicines and the development of biopharmaceutical businesses.

KEY MARKET PLAYERS:

GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Medtronic, B. Braun Melsungen AG, Aramark, BC Technical, Inc., Alliance Medical Group, and Althea Group are a few of the companies playing a vital role in the Europe monoclonal antibody therapy market profiled in this report.